JY BioMed Announces Publication in Cancer Letters: Novel Heavy-Chain ADC Demonstrates Breakthrough Efficacy Against Brain Metastases

2 days ago
2 min read

Taipei, Taiwan – April 2026 — JY BioMed Co., Ltd. today announced the publication of its latest research in the internationally renowned journal Cancer Letters, highlighting a novel antibody-drug conjugate (ADC) platform targeting CEACAM6 for the treatment of aggressive cancers, including brain metastases.

The study, titled “A heavy-chain antibody-drug conjugate targeting glycosylated CEACAM6 inhibits brain metastatic tumor growth,” was conducted in collaboration with Taipei Medical University (TMU) and its affiliated medical centers, reflecting a strong integration of academic excellence and translational research capabilities.

A Next-Generation ADC Platform Targeting Unmet Clinical Needs

Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology; however, conventional IgG-based ADCs are often limited by poor tumor penetration and restricted access to glycosylation-masked epitopes.

JY BioMed’s proprietary humanized heavy-chain antibody (hHCAb) platform addresses these limitations through:

Reduced molecular size (~80 kDa), enabling superior tumor penetration
Ability to recognize glycosylated CEACAM6 epitopes inaccessible to conventional antibodies
Enhanced delivery capability in challenging environments such as the blood–brain barrier

CEACAM6 is a clinically validated tumor-associated antigen widely expressed in lung, colorectal, and pancreatic cancers, making it an attractive target for next-generation therapeutics.

Robust Preclinical Efficacy Across Multiple Tumor Models

The study demonstrates that the CEACAM6-targeting hHCAb-ADC exhibits strong and selective anti-tumor activity:

Sub-nanomolar cytotoxicity against CEACAM6-positive cancer cells
Minimal toxicity toward normal cells, including PBMCs and fibroblasts
Bystander killing effect, enabling elimination of heterogeneous tumors
Superior tumor penetration in patient-derived organoid models

In multiple in vivo models, the therapy achieved:

Complete tumor regression at low doses (as low as 0.2 mg/kg)
Significant tumor growth suppression in colorectal, lung, and pancreatic cancer models
Superior efficacy compared with conventional ADCs and standard-of-care therapies

Breakthrough Potential in Brain Metastasis Treatment

One of the most notable findings of the study is the ability of the hHCAb-ADC to effectively target brain metastases—an area where current ADCs have shown limited success.

In an intracranial lung cancer model:

The therapy achieved ~48.5% tumor volume reduction (TVR)
Demonstrated effective penetration into brain tumors
Delivered more consistent anti-tumor activity compared to existing targeted therapies

These results highlight the potential of the hHCAb platform to overcome the blood–brain barrier, a major challenge in oncology drug development.

Strong Translational Relevance and Clinical Development Potential

The study further demonstrated favorable properties supporting clinical translation:

High binding affinity (picomolar range) and target specificity
Tumor-selective distribution with minimal off-target accumulation
Strong stability and favorable preliminary safety profile
Broad applicability across multiple CEACAM6-expressing tumor types

Importantly, this publication represents a collaborative effort between JY BioMed and Taipei Medical University (TMU), a leading academic medical institution in Asia, underscoring JY BioMed’s ability to bridge cutting-edge science with clinical application through strategic academic partnerships.

JY BioMed holds patents and intellectual property rights covering the heavy-chain antibody (HCAb), humanized HCAb, and ADC technologies described in this study.

About JY BioMed

JY BioMed is a biotechnology company focused on developing next-generation cancer therapeutics, including antibody-drug conjugates, gamma delta T cell therapies, and precision oncology platforms. The company is committed to translating innovative science into clinically impactful treatments for patients with unmet medical needs.